Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381737480> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4381737480 endingPage "3105" @default.
- W4381737480 startingPage "3097" @default.
- W4381737480 abstract "Background/Aim: The efficacy and safety of bevacizumab for ovarian cancer have been reported in randomized phase III clinical trials. It is important to gather experience and data in a real-world setting. The objective of the present study was to evaluate the efficacy and safety of bevacizumab for patients with ovarian cancer in a real-world setting. Patients and Methods: For front-line settings, patients with FIGO stage III-IV ovarian cancer treated using bevacizumab and chemotherapy after debulking surgery (Chemo + Bev group, n=79), in addition to those treated with only chemotherapy after debulking surgery (Chemo group; n=66), at our institute were reviewed retrospectively. For recurrent settings, patients with recurrent ovarian cancers treated with bevacizumab and any chemotherapy were reviewed retrospectively (n=65). Results: In the front-line setting, the disease-free survival was significantly longer in the Chemo + Bev group compared with that in the Chemo group (p=0.021). Hypertension and proteinuria were found to be statistically more frequent in the Chemo + Bev group compared with that in the Chemo group (p=0.002 and p=0.004). In the recurrent setting, in platinum-sensitive patients, the response rate (RR) and the disease control ratio (DCR) were 78.4 and 94.1%, respectively. In platinum-resistant patients, the RR and the DCR were 28.6 and 57.1% respectively. The median progression-free survival was 18.3 and 7.1 months for platinum-sensitive recurrence and platinum-resistant recurrence, respectively. The major ≥ grade 3 adverse event was neutropenia. Conclusion: The present study provided encouraging real-world evidence of the efficacy and safety of bevacizumab for ovarian cancer in real-world." @default.
- W4381737480 created "2023-06-24" @default.
- W4381737480 creator A5001196940 @default.
- W4381737480 creator A5002025978 @default.
- W4381737480 creator A5015074866 @default.
- W4381737480 creator A5022640516 @default.
- W4381737480 creator A5030752431 @default.
- W4381737480 creator A5042218973 @default.
- W4381737480 creator A5059458078 @default.
- W4381737480 creator A5065367444 @default.
- W4381737480 creator A5070815122 @default.
- W4381737480 creator A5076997884 @default.
- W4381737480 date "2023-06-23" @default.
- W4381737480 modified "2023-10-14" @default.
- W4381737480 title "Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience" @default.
- W4381737480 doi "https://doi.org/10.21873/anticanres.16481" @default.
- W4381737480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37351971" @default.
- W4381737480 hasPublicationYear "2023" @default.
- W4381737480 type Work @default.
- W4381737480 citedByCount "0" @default.
- W4381737480 crossrefType "journal-article" @default.
- W4381737480 hasAuthorship W4381737480A5001196940 @default.
- W4381737480 hasAuthorship W4381737480A5002025978 @default.
- W4381737480 hasAuthorship W4381737480A5015074866 @default.
- W4381737480 hasAuthorship W4381737480A5022640516 @default.
- W4381737480 hasAuthorship W4381737480A5030752431 @default.
- W4381737480 hasAuthorship W4381737480A5042218973 @default.
- W4381737480 hasAuthorship W4381737480A5059458078 @default.
- W4381737480 hasAuthorship W4381737480A5065367444 @default.
- W4381737480 hasAuthorship W4381737480A5070815122 @default.
- W4381737480 hasAuthorship W4381737480A5076997884 @default.
- W4381737480 hasBestOaLocation W43817374801 @default.
- W4381737480 hasConcept C121608353 @default.
- W4381737480 hasConcept C126322002 @default.
- W4381737480 hasConcept C141071460 @default.
- W4381737480 hasConcept C143998085 @default.
- W4381737480 hasConcept C197934379 @default.
- W4381737480 hasConcept C2776694085 @default.
- W4381737480 hasConcept C2777063308 @default.
- W4381737480 hasConcept C2777802072 @default.
- W4381737480 hasConcept C2780427987 @default.
- W4381737480 hasConcept C2781100745 @default.
- W4381737480 hasConcept C71924100 @default.
- W4381737480 hasConceptScore W4381737480C121608353 @default.
- W4381737480 hasConceptScore W4381737480C126322002 @default.
- W4381737480 hasConceptScore W4381737480C141071460 @default.
- W4381737480 hasConceptScore W4381737480C143998085 @default.
- W4381737480 hasConceptScore W4381737480C197934379 @default.
- W4381737480 hasConceptScore W4381737480C2776694085 @default.
- W4381737480 hasConceptScore W4381737480C2777063308 @default.
- W4381737480 hasConceptScore W4381737480C2777802072 @default.
- W4381737480 hasConceptScore W4381737480C2780427987 @default.
- W4381737480 hasConceptScore W4381737480C2781100745 @default.
- W4381737480 hasConceptScore W4381737480C71924100 @default.
- W4381737480 hasIssue "7" @default.
- W4381737480 hasLocation W43817374801 @default.
- W4381737480 hasLocation W43817374802 @default.
- W4381737480 hasOpenAccess W4381737480 @default.
- W4381737480 hasPrimaryLocation W43817374801 @default.
- W4381737480 hasRelatedWork W2065800215 @default.
- W4381737480 hasRelatedWork W2072213084 @default.
- W4381737480 hasRelatedWork W2133480631 @default.
- W4381737480 hasRelatedWork W2148187838 @default.
- W4381737480 hasRelatedWork W2911758317 @default.
- W4381737480 hasRelatedWork W3097676887 @default.
- W4381737480 hasRelatedWork W4297961826 @default.
- W4381737480 hasRelatedWork W4309150657 @default.
- W4381737480 hasRelatedWork W4376644351 @default.
- W4381737480 hasRelatedWork W59268075 @default.
- W4381737480 hasVolume "43" @default.
- W4381737480 isParatext "false" @default.
- W4381737480 isRetracted "false" @default.
- W4381737480 workType "article" @default.